Comparison
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874 vs 3q13 Microdeletion Syndrome C2931338
Clinical comparison between 46 XX Disorder OF Sex Development Induced BY Exogenous Maternal Derived Androgen and 3q13 Microdeletion Syndrome for differential diagnosis and treatment planning.
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
A condition caused when a pregnant person takes hormone medications containing androgens, affecting fetal development. The fetus has XX chromosomes. Stopping the offending agent is key, with specialist care for affected infants.
3q13 Microdeletion Syndrome C2931338
A genetic disorder from missing material on chromosome 3q13, associated with developmental delays, intellectual disability, and various congenital features.
6 comparison axes
Onset
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
Variable
3q13 Microdeletion Syndrome C2931338
Variable
Onset patterns differ
Severity
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
severe
3q13 Microdeletion Syndrome C2931338
moderate
Different severity levels
Chronic
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
Chronic
3q13 Microdeletion Syndrome C2931338
Chronic
Differing course
Communicable
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
No
3q13 Microdeletion Syndrome C2931338
No
Different transmission
Body System
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
reproductive
3q13 Microdeletion Syndrome C2931338
congenital
Same/different system
Category
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
endocrine
3q13 Microdeletion Syndrome C2931338
genetic
Different category
Bottom line
46-xx-disorder-of-sex-development-induced-by-exogenous-maternal-derived-androgen-C5679874 and 3q13-microdeletion-syndrome-C2931338 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874 | 3q13 Microdeletion Syndrome C2931338 | Discriminating power |
|---|---|---|---|
| Genital development | Atypical genital development may occur in an XX fetus after androgen exposure. | Genital findings are not the defining feature and are not established here. | Moderate |
| Neurodevelopment | Developmental delay is not the core described feature. | Developmental delay and intellectual disability are associated features. | High |
| Exposure history | History of androgen-containing medication during pregnancy is central. | No medication exposure is required; chromosomal material is missing. | High |
When to favor each condition
Choose 46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874 when
XX karyotype with suspected prenatal androgen exposure
The supplied description centers on exogenous maternal androgen affecting an XX fetus.
High
Need to stop an implicated hormone medicine
Stopping the offending agent is described as key, with specialist infant care.
Moderate
Reproductive-system focused evaluation
The listed body system is reproductive and the category endocrine.
Moderate
Choose 3q13 Microdeletion Syndrome C2931338 when
Developmental delay with congenital features
The description associates 3q13 deletion with delay, disability, and congenital findings.
Moderate
Suspected chromosomal microdeletion
Etiology is missing chromosome 3q13 material rather than hormone exposure.
High
Broader congenital syndrome assessment
The listed system is congenital and the category genetic.
Moderate
How key tests differ
| Test | 46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874 | 3q13 Microdeletion Syndrome C2931338 | Interpretation |
|---|---|---|---|
| Karyotype | XX chromosomes are described. | Karyotype result is not specified in the source. | An XX result supports the left context but does not exclude other conditions. |
| Chromosomal microarray | No microdeletion is required by the description. | May identify missing 3q13 material when clinically indicated. | A deletion finding supports the right diagnosis only with clinician review. |
| Medication and pregnancy history | Androgen-containing hormone use is relevant. | Not an etiologic requirement. | History can distinguish exposure-related concern from a genetic syndrome. |
Prognosis comparison
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
- Outcome
- Course is described as chronic and severe, but individual outcome is not established.
- Factors
- Timing and nature of exposure, findings at birth, and access to specialist care.
3q13 Microdeletion Syndrome C2931338
- Outcome
- Course is chronic and moderate in the source, with variable developmental impact.
- Factors
- Deletion extent, associated congenital features, and developmental support.
Time frame: From prenatal or congenital recognition into long-term follow-up; exact timelines are not established.
Etiology, clinical findings, comorbidities, and coordinated specialist care.
Complications comparison
| Complication | Presentation |
|---|---|
| Sex-development concerns | May affect fetal genital development; extent varies. Not established as a characteristic complication. Specialist assessment is needed; do not infer a specific phenotype. |
| Developmental disability | Not established from the supplied description. Intellectual disability and developmental delay are associated. Severity and functional impact vary and are not quantified here. |
| Congenital anomalies | Beyond sex development, anomalies are not specified. Various congenital features are described, without a fixed list. Individual evaluation should define which features are present. |
Patient education highlights
- HighDifferent causes
One concern follows pregnancy androgen exposure in an XX fetus; the other is a chromosomal deletion.
- HighSpecialist care
Endocrine, genetics, and pediatric specialists should interpret results and guide care.
- MediumAvoid unsupported numbers
Prevalence, exact laboratory cutoffs, mortality, and treatment doses are not established here.